Home/Filings/4/0001104659-25-066765
4//SEC Filing

Rickard Kathleen A. 4

Accession 0001104659-25-066765

CIK 0001657312other

Filed

Jul 8, 8:00 PM ET

Accepted

Jul 9, 6:39 PM ET

Size

12.7 KB

Accession

0001104659-25-066765

Insider Transaction Report

Form 4
Period: 2025-07-07
Rickard Kathleen A.
Chief Medical Officer
Transactions
  • Tax Payment

    Ordinary Shares

    2025-07-08$11.44/sh37,616$430,3762,594,920 total
  • Exercise/Conversion

    Restricted Share Units

    2025-07-0786,064167,056 total
    Ordinary Shares (86,064 underlying)
  • Award

    Restricted Share Units

    2025-07-07+253,120253,120 total
    Ordinary Shares (253,120 underlying)
  • Exercise/Conversion

    Ordinary Shares

    2025-07-07+86,0642,632,536 total
Footnotes (6)
  • [F1]Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
  • [F2]Represents the number of Ordinary Shares withheld to satisfy the tax withholding obligation in connection with the vesting of certain previously reported Restricted Share Units.
  • [F3]The price reported represents the closing price of the Issuer's ADSs on the Nasdaq Stock Market LLC on July 3, 2025 divided by eight (8).
  • [F4]Consists of (i) 659,984 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 82,498 ADSs); and (ii) 1,934,936 Ordinary Shares underlying 241,867 ADSs.
  • [F5]Represents an award of performance-based Restricted Share Units ("RSUs") covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date.
  • [F6]The RSUs were earned upon the determination by the Board of Directors of the Issuer (the "Determination Date") that certain performance metrics related to Q2 2025 had been achieved. The RSUs vested as to 34% of the total shares on the Determination Date, and vest as to the remainder of the shares in equal quarterly installments over a two year period on each of November 1, February 1, May 1 and August 1, subject to the Reporting Person's continued service to the Issuer on each vesting date.

Issuer

Verona Pharma plc

CIK 0001657312

Entity typeother

Related Parties

1
  • filerCIK 0001836883

Filing Metadata

Form type
4
Filed
Jul 8, 8:00 PM ET
Accepted
Jul 9, 6:39 PM ET
Size
12.7 KB